US › Healthcare

Molecular Partners AG ADR (MOLN)

US · Healthcare · Biotechnology

$4.16+0.97%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-13.1M

Profit YoY

+29.5%

EPS

$-0.45

EPS estimate

$-0.41

EPS came in at -0.45 against a street estimate of -0.41 — a miss of 8.1%.

Key statistics

Market cap

$147.4M

Forward P/E

1.7

P/B

1.75

Book value

$2.26

EPS (TTM)

$-1.91

52-week high

$5.36

52-week low

$3.46

50-day MA

$3.95

200-day MA

$4.20

Beta

0.67

Analyst view

Analysts rate Molecular Partners AG ADR a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $11.12.

Shareholding

Institutions

9.58%

Largest institutional holders

Fund	Stake
Suvretta Capital Management, LLC	5.92%
Bvf Inc	3.61%
SmartHarvest Portfolios, LLC	0.04%
Morgan Stanley - Brokerage Accounts	0.00%
EverSource Wealth Advisors, LLC	0.00%
UBS Group AG	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Molecular Partners AG ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.